Although the trial results CureVac published aren’t directly comparable, and the proliferation of viral variants has complicated studies since the other shots were tested last year, experts say key differences between the vaccines probably played a major role in weak results
Market – Overview:Egg products have been an essential part of many cuisines around the world, citing population rise the demand for egg and egg products has also increased significantly.Market Research Future, a firm which specializes in market reports related to the Food and Beverage sector among others, recently published a report on this market.The industry is expected to expand with a CAGR of 4.5% during the forecast period.Increase in population along with the increase in the number of applications for egg and egg products has boosted the level of market growth of this sector.Development of varieties of eggs and egg products will fuel the onward expansion of the sector.Access Report Details @ https://www.marketresearchfuture.com/reports/egg-products-market-3859Industry Segments:The market for eggs and egg products is initially segmented on the basis of form which comprises of dried, liquid, others.Applications of egg and egg products includes food such as ready-to-eat meals, confectionery, bakery, dips & sauces, dairy products, horeca and non-food items like personal care, animal feed, medicines & vaccines among others.However, food based uses govern the share among the various applications of egg and egg products owing to increasing consumers demand for ready-to-eat meals and bakery products.Detailed Regional Analysis:The global egg and egg products market includes regions such as North America, Europe, Asia Pacific, and Rest of the World (RoW).
Global Medical Drones Market Trending in 2021New York, NY 18 June 2021: The global medical drones market size is expected to reach USD 947.6 million by 2027 according to a new study by Polaris Market Research.The report “Medical Drones Market Share, Size, Trends, Industry Analysis Report, Drone Type (Fixed Wing, Rotor Drone and Hybrid Drones); By Application (Blood transfer, Drugs/Pharmaceutical Transfer, Vaccination Programs), End-Use (Emergency Medical Services, Government Organizations, and Blood Banks), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Medical drones refer to the aerodynamic pods that are being deployed to transport key medical supplies that comprises of primary medical aids, vaccines, and drugs.Through the development of highly advanced technology has resulted in notable adoption of medical drones across the hospitals and military bases.Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/medical-drones-market/request-for-sampleFurther, the impressive capability of these drones to make a flight over the closed zones and that too without any requirement of crew is the key reason for their high demand.Some other major benefits include, transporting blood samples or other lab samples to remote and small hospitals and clinics; medical support or telemedicine including, drugs, diagnostics, or key medical tools that include, portable ultrasound to remote locations or tough military terrain.Market participants such as Zipline, DJI, DHL, TUDelft, Flirtey, Embention, Matternet, Vayu, and EHang are some of the key players operating in the global market.Zipline drones, the frontrunner in the market, have cumulatively flown more than 1 million kilometres in Rwanda with more than 13 thousand deliveries.
Keir Starmer has hit out at claims that the government suppressed furlough funding for sick workers self-isolating at the height of the Covid pandemic.The Labour leader waded into the row after it emerged that senior civil servants had complained that the Treasury was worried about publicising a relatively unknown provision in the furlough rules that allows temporary payments for staff forced to quarantine.The Politico.eu website said it had seen emails, dated from January and February this year, showing that officials had complained about the failure to make employers and staff aware of the guidance.“Furlough can be used to cover self-isolation, but [the Treasury] are reluctant to say this explicitly in guidance because it could lead to employees being furloughed who do not need to be,” one email read. “This is a live issue being worked through.”One senior official explained in their complaint: “Incentive payments are too low to incentivise employees to take tests due to risk of loss of income.”Both Downing Street and the Treasury insisted that the guidance was clear on the government’s own website that the furlough scheme had never been intended to be used as a substitute for statutory sick pay.But Labour said the revelations were “shameful and reckless”, with Starmer adding he was “really concerned” about any suggestion of restricting cash help for home quarantine.“One of the big issues for the 14 months or so we have been in the pandemic has been whether people feel that they can afford to self-isolate,” he told reporters during a visit to Airbus in Bristol.“Self-isolation is a huge tool in the armoury when it comes to defeating the pandemic, but too many people felt that they couldn’t afford to self-isolate.“We have been saying this for a year or more, so the idea now that this has been suppressed I think is so wrong in terms of how we fight this pandemic.”Shadow Treasury minister Bridget Phillipson added: “It is shameful and reckless that the Chancellor ignored professional advice and put countless people and workplaces at unnecessary risk when he had the opportunity to help.”The government guidance for firms makes clear that short-term illness or isolation “should not be a consideration when deciding if you should furlough an employee”.But it adds: “If, however, employers want to furlough employees for business reasons and they are currently off sick, they are eligible to do so, as with other employees. In these cases, the employee should no longer receive sick pay and would be classified as a furloughed employee.”Government sources said that the reason for the rules was that HM Revenue & Customs would have no mechanism or way of identifying those being furloughed for short term sickness, and it could open the whole scheme to fraud risk.The prime minister’s official spokesperson said: “The guidance on Gov.uk sets out that the furlough scheme is not intended for short-term absences from work due to sickness and self-isolation should not be a consideration when a business is deciding if a business should furlough an employee.”A Treasury spokesperson added: “It has always been clear that the purpose of the furlough scheme is to support jobs – we’ve been upfront about that from the start.“We have a specific support package in place for those self-isolating due to coronavirus, including £500 one off payments for those on low incomes.“If an employer wants to furlough an employee for business reasons and they are currently off sick then they are eligible to do so as with other employees. This has been set out in guidance since April last year.”Separately, Downing Street tried to play down reports that ministers would legislate to allow a legal right to work from home because of the pandemic.“We’ve asked people to work from home where they can during the pandemic but there are no plans to make this permanent or introduce a legal right to work from home,” the PM’s spokesperson said.“There’s no plans to make working from home permanent or introduce a legal right to work from home.”But he added the government was committed in its manifesto to a possible default right to flexible working. “What we’re consulting on is making flexible working a default option, unless employers have good reasons not to.”He defined flexible working as “a range of working arrangements around time, place and hours of work including part-time working, flexi-time or compressed hours” but not necessarily working from home.Related...Test And Trace Boss Dido Harding Has Applied To Run The NHSMichael Gove Faces A Double Grilling In Fiery BBC Breakfast And GMB InterviewsHancock Confirms Plan To Make Covid Vaccines Compulsory For All NHS And Care Workers
Market AnalysisThe global companion, animal healthcare market, is predicted to touch USD 20 billion at a 9.6% CAGR over the forecast period (2017-2023), as per the latest Market Research Future (MRFR) report.A yearly veterinary checkup is one of the finest means of keeping the pet healthy.Various factors are propelling the companion animal healthcare market growth.Additional factors pushing market growth include growing investments made by key players for developing advanced pet care solutions, increasing awareness about animal cruelty, advances in animal vaccines and health medicines, and increased types of medical treatment.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/1168Market SegmentationThe Market Research Future report provides a wide segmental analysis of the companion animal healthcare market based on end users, diagnostic tests, and product.Based on product, the companion animal healthcare market is segmented into vaccines, pharmaceuticals, and feed additives.Of these, the pharmaceutical products segment will have the largest share in the market over the forecast period.This is owing to rising zoonotic infections that is boosting the need for establishing point-of-care testing and diagnostics laboratories.Based on end users, the companion animal healthcare market is segmented into home care, veterinary clinics, and veterinary hospitals.This is owing to the accessibility of a huge variety of diagnostic options.Regional AnalysisBased on the region, the companion animal healthcare market report covers the latest trends and growth opportunities across the Asia Pacific, Europe, the Americas, and the Middle East and Africa.
Recently, scientists at Stanford University published a gene sequencing file of Moderna's COVID-19 vaccine on the open-source code repository GitHub, deciphering the mRNA sequence of the vaccine for the first time.Although the RNA sequence information does make the vaccine more accessible in a sense, it is still difficult to establish a supply chain and actually produce the vaccine on a large scale.It is reported that the work was completed by scientists from Stanford University, who said that the starting point is public welfare.For example, the synthesis and formulation steps included in the vaccine production process, such as preparation and encapsulation, involve very complex synthetic chemistry, enzyme chemistry, and membrane dynamics.The speed of vaccine development has also exceeded expectations, which not only proves that the biotechnology and pharmaceutical industries can respond to urgent and unmet global needs, but also proves the inherent ability of mRNA as a medicine.However, due to the instability of mRNA molecules, high innate immunogenicity, and low delivery efficiency in vivo, the application of mRNA vaccines has been limited.
Global Meningococcal Vaccines Market: OverviewThis report analyzes the current and future scenario of the global meningococcal vaccines market.Additionally, the section comprises a competitive matrix and company profiles along with business overview to understand the competitive landscape in the market.This section of the report also provides market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market.Request For Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1666Global Meningococcal vaccines Market: Key SegmentsThe global meningococcal vaccines market has been segmented based on type, end-user, and region.The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.Enquiry Before Buying – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB_id=1666Global Meningococcal vaccines Market: Regional OutlookIn terms of region, the global meningococcal vaccines market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and rest of Middle East & Africa).The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.The major players profiled in the market report include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt.
Global Veterinary Vaccines Market: OverviewVaccines are products designed to trigger immune response to fight future infection.The global veterinary vaccines market is expanding at a significant pace due to factors such as new technological advances in vaccines development, continuous development of drug resistance by pathogens, and emergence of new diseases.The global veterinary vaccines market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.Additionally, the section comprises a competitive matrix and company profiles to understand the competitive landscape in the market.This section of the report also provides market attractiveness analysis by geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global veterinary vaccines market.Request For Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=215Global Veterinary Vaccines Market: Key SegmentsIn terms of technology, the global veterinary vaccines market has been segmented into inactivated vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines.In terms of animal, the global veterinary vaccines market has been classified into companion animal vaccines and livestock animal vaccines.The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.Request For Covid19 Impact Analysis Across Industries And Markets @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=215Global Veterinary Vaccines Market: Regional OutlookIn terms of geography, the global veterinary vaccines market has been segmented into five major regions and key countries/sub-regions in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and Rest of Middle East & Africa).
Reports and Data has recently published a new research report on Global Live Vaccines Market that covers current development scenario and emerging trends of the market.The research report provides a comprehensive assessment of the market size, market share, revenue growth, and provides a futuristic perspective about the market trends, growth factors, facts, and industry validated market data.The report applies advanced statistical tools such as Porter’s Five Forces analysis and SWOT analysis to shed light on the competitive landscape of the global Live Vaccines market.The report covers all the critical and essential information relating to the global Live Vaccines market which helps the readers and clients gain a thorough understanding of the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2078The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers.The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors.It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.Key Companies in the market include:Merck & Co., GlaxoSmithKline plc., Astellas Pharma Inc., Emergent BioSolutions, AstraZeneca plc, Serum Institute of India Pvt.
Why does the industry require Clinical Data Management?The industry requires Clinical Data Management because drugs, treatment methods, vaccines etc.ate launched in the market based on the results of clinical trials.Clinical research courses would also tell one how data is significant fir Government agencies, medical communities and patients.Yet, one must understand that tasks are complex in terms of gathering hundreds of clinical trial data points in a compliant manner.Thus, these professionals are prepared by industry experts at clinical data management course.Key Responsibility of Clinical Data ManagersClinical Data Managers have several responsibilities which they have to carry out during the proceedings of a clinical trial.Yet, clinical research courses educate students about the key responsibility which is to create case report forms (CRF) for the collection of clinical trial data.
The NHS app has been updated with a new ‘Covid Pass’, which can be used to show vaccination status and test results. The app already displayed how many vaccines a person has received and when, but the new function allows users to display any recent Covid-19 test results, too. It means those who have yet to be double vaccinated can take a lateral flow test at home and log it on the app before attending a venue. Spot tests will ensure people are being truthful about their negative results, the Daily Mail reports.The NHS App, where the NHS Covid Pass is available, is different to the NHS Covid-19 app used for contact tracing.The app’s new function has been primarily designed to aid large events, including Wimbledon and Euro 2020 matches, which are part of the government’s events research programme. At Wimbledon, for example, anyone attending as a fan will need to either show proof of full vaccination, a negative lateral flow test or immunity through a recent Covid infection (a positive PCR test in the previous 180 days).Outside of these official pilot events, the government has said that displaying vaccination status won’t be made mandatory, but event organisers will be given the option to ask attendees to show their Covid status. HuffPost UK has contacted the government for further clarity on which business may be encouraged to use the app’s function in the coming months and will update this article when we receive a response. There has already been widespread criticism surrounding the concept of domestic “Covid passports”. Wetherspoon boss Tim Martin previously said vaccine passports would be “the last straw” for struggling pubs. Meanwhile, a cross-party group of MPs working with the Commons Public Administration and Constitutional Affairs Committee (PACAC) urged the government not to introduce Covid passports for domestic use. They argued that passports would “disproportionately discriminate” based on race, religion, age and socio-economic background. Internationally, though, health ministers from G7 countries agreed on the need to work together to develop “mutual recognition of testing and vaccination certificates across countries”. Vaccine passports appear likely around international travel. Despite the new app update, a government spokesperson told PA a review of the evidence around Covid certification was still ongoing.READ MORE:Delta Variant Symptoms Might Be Different To What We're Used ToWill Lockdown Be Extended Again?You're Finally Vaccinated, But Don't Forget These 5 PrecautionsThe 'Game-Changing' Antibody Tests That Could Detect Covid Variants
Market Analysis: Global Cell Culture Products MarketCell culture products market is set to witness a substantial CAGR in the forecast period of 2019- 2026.Growing demand for single- use technologies and technological advancement in healthcare industry is the factor for the market growth.Market Definition: Global Cell Culture Products MarketCell culture is a process which is used to develop, propagate and grow a big number of cells in a platter.They are mainly used to test new drugs, and diagnose infections.Cell culture enables one to develop cells outside their natural environment and regulate their growing circumstances.Cell culture is one of the main instruments used in cellular and molecular biology, offering great modeling technologies for the study of ordinary cell physiology and biochemistry, mutagenesis, carcinogenesis, and the cell effects of drugs and toxic compounds.Get More Insights About Global Cell Culture Products Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cell-culture-products-marketMarket DriversGrowing awareness about the advantages of cell culture-based vaccines will drive this market growthAvailability of advanced cell culture products also accelerates the growth of this marketIncreasing funding for cell-based research acts as a market driverRising prevalence for chronic diseases drives the market growthMarket RestraintsHigh cost of research in cell biology will hamper the market growthDearth of proper infrastructure for cell-based research will also hinder the market growthStrict rules and regulations associated with cell culture production is another factor restricting this market growthSegmentation: Global Cell Culture Products MarketBy ProductConsumablesSera, Media, and ReagentsMediaSpecialty MediaStem Cell Culture MediaClassical Media & SaltsSerum-Free MediaReagentsCryoprotective ReagentsOther Cell Culture ReagentsContamination Detection KitsAntibiotics/AntimycoticsAttachment & Matrix FactorsBalanced Salt SolutionsCell Dissociation ReagentsBuffers & ChemicalsSupplements & Growth FactorsSeraOther Animal SeraAdult Bovine SeraFetal Bovine SeraVesselsPetri DishesFlasksMultiwell PlatesCell Factory Systems/Cell StacksRoller/Roux BottlesBioreactor AccessoriesEquipmentSupporting EquipmentOther Supporting EquipmentBiosafety CabinetsMicroscopesAutoclavesCentrifugesCarbon Dioxide IncubatorsCell CountersFiltration SystemsBioreactorsSingle-Use BioreactorsConventional BioreactorsStorage EquipmentCryostorage SystemsRefrigerators & FreezersBy Cell Culture ApplicationBiopharmaceutical/TherapeuticsTherapeutic ProteinsVaccine ProductionStem Cell TechnologyCancer ResearchDrug Screening & DevelopmentTissue Engineering & Regenerative MedicineOthersBy End- UsersPharmaceutical & Biotechnology CompaniesHospitals and Diagnostic LaboratoriesResearch InstitutesCell BanksBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia-PacificSouth AmericaBrazilRest of South AmericaMiddle East and AfricaSouth AfricaRest of Middle East and AfricaKnow more about this report https://www.databridgemarketresearch.com/reports/global-cell-culture-products-marketKey Developments in the Market:In May 2018, Greiner Bio-One North America, Inc. announced the acquisition of 3D Cell Culture Technology.This acquisition will help the company to advance scientific research and enhance health while offering scientists with access to the best products.
The rise in COVID-19 cases indicates the second wave in India.The death rate due to COVID-19 has been recorded its highest since January this year according to the Union Health Ministry data.While a range of COVID vaccines have surged a relief, seeing the rise in COVID cases means people must take precautions and follow remedies and routines to build their immunity.Furthermore, the Ministry of AYUSH, India has suggested dietary measures that include turmeric milk, chyawanprash, and other ayurvedic herbs to prevent coronavirus infection.This has led to a shift in consumer behavior towards using more Ayurveda and Natural Care immunity-boosting products.When it comes to the regular consumption of chyawanprash, Dabur has been the first choice for consumers in India.With the company’s 136 years-long legacy and the motto of being ‘dedicated to the Health & Well-Being of every household’, the brand shares a strong bond of trust that has been immunizing millions of families in Indian households.During the COVID crisis, the brand Dabur took an ambitious step to further immunize the trust among its consumers by undertaking a clinical study adhering to the GCP guidelines to test the immunity-boosting power of Dabur Chyawanprash.The findings revealed that 1 out of 42, tested positive for COVID-19 in the control group who regularly consumed Dabur Chyawanprash.However, the control group who were not consuming Dabur Chyawanprash showed a 28.57% risk of infection with 28 out of 42 people testing positive for COVID-19.This study has been registered with the Clinical Trials Registry of India, a portal of ICMR.
The demand within the global market for vaccines has been rising on account of advancements in the field of medical therapy and disease prevention, finds Transparency Market Research (TMR).The historic trends have been suggestive of the opportunities that have aided market growth in recent times.The competition in the global vaccines market has further escalated on account of the emergence of newbie vendors in the global vaccines market.Some of the key players in the global vaccines market are CSL Ltd, Janssen Pharmaceutical Company, GlaxoSmithKline plc., Pfizer, Inc., Mitsubishi Tanabe Pharma Corporation, and Sanofi Pasteur SA.Transparency Market Research (TMR) predicts that the global market for vaccines would expand at a healthy CAGR of 6.0% over the period between 2017 and 2025.Based on geography, the market for vaccines in Europe is projected to accumulate humongous revenues in the years to come.Request COVID Analysis on Vaccine Study Analysis Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=21 Availability of Vaccines for Kids to PropelsThe global market for vaccines caters to the masses of all age groups, including children.Furthermore, the market for vaccines has also expanded on account of the growth of new and advanced facilities across medical facilities such as healthcare centers and hospitals.
As we continue to wait for the safe and successful roll out of the COVID-19 vaccine, many of us logistical thinkers are left wondering: how are they going to do it?The answer lies within the real hero behind the scenes for pharmaceutical refrigeration: dry ice.We’ve spoken to the Cold Jet experts where you can buy dry ice Cold Jet products for the safe refrigeration of food, food processing, pharmaceuticals and catering to get a better understand of the role of dry ice in vaccination programs for COVID-19.How Is Dry Ice Helping with the Coronavirus Vaccine Program?We know that the COVID-19 vaccines and the procedure of the vaccine programs requires ultra low temperatures and freezers.To achieve this, the vials of the frozen vaccine are being shipped and stored in insulated thermal shipping containers containing dry ice.
(University of California - San Diego) UC San Diego School of Medicine researchers discovered that the enzyme RNA polymerase II recognizes and transcribes artificially added base pairs in genetic code, a new insight that could help advance the development of new vaccines and medicines.
Vaccines are effective against the variant, but experts worry about states where fewer people are inoculated.
“Brevity is the soul of wit/And tediousness the limbs and outward flourishes.” Thanks to his latest long, long blogpost, Dominic Cummings has perhaps proved one thing beyond doubt: he’s no student of Shakespeare.With his 7,286 words, wonky screenshots and phone snaps, Boris Johnson’s former chief adviser displayed once more a literary incontinence that only the internet can allow. It was not so much a stream of consciousness as a scream of bumptiousness, laced with venom.Cummings’ new opus was seen as both tedious and treacherous by many Tory MPs, who share a mutual loathing with the ex-Vote Leave chief. The public too appear to have long ago concluded that he is far from a credible witness in any prosecution case against Johnson’s failings on Covid.The mastermind of the £350m-a-week-for-the-NHS on that bus, the genius behind the ‘76 million Turks are joining the EU’ poster, is hardly the man to lead the charge against lying in politics.And there’s no question that Cummings is in many ways his own worst enemy. His renewed character assassination attempt on Matt Hancock was so relentless that it undermined some of the more sensible points he tried to make about the failures of governance at the start of the pandemic. Talk about blogging a dead horse, we get that he hates Hancock already.Yet if you got beyond the word-blizzard, the repeated use of italics for emphasis, the ACRONYMS and bolded out jargon, the obsessive lists of lettered (A to E) and numbered (1 to 4) paragraphs, there were some nuggets that ought to concern everyone well before the public inquiry begins.Hancock’s claim in March to have got PPE supplies “all sorted” was undermined by an official telling Cummings that procurement rules and cost concerns meant masks, gloves and gowns being shipped rather than flown from China. Most damning of all was Johnson’s WhatsApp message, “On PPE it’s a disaster. I can’t think of anything except taking Hancock off and putting Gove on.”Similarly, on delays in getting more ventilators, the PM’s verdict was just as withering: “It’s Hancock. He has been hopeless.” And on the health secretary’s failure to get more Covid testing, Johnson upped the disdain with that eye-catching expletive: “Totally fucking hopless.”It’s worth saying that on the central charge that Hancock “lied”, the jury remains out because there is no recording of what he actually promised in the Cabinet room. Cummings again claimed cabinet secretary Mark Sedwill said that he and other ministers and officials lacked confidence in Hancock’s “honesty”.But while saying this conversation was “reinforced in written exchanges”, he failed to publish them. We now await for the Commons select committees to get Sedwill’s own version. I recall No.10 admitting it hadn’t contacted the former cabinet secretary (who, let’s not forget, Cummings helped to oust from his job). Surely the MPs have asked him about such a serious charge?Given that Cummings’ blog dropped shortly before PMQs, some have accused Keir Starmer of missing an open goal by failing to quote the “fucking hopeless” claim. Yet I can see why the Labour leader opted not to focus on Hancock, partly because blaming him may end up being Johnson’s alibi come any public inquiry. “Hopeless Hancock” could be reshuffled soon, too.Starmer did quote Cummings, but only on his previous claim that Johnson had a chaotic border policy. He realised that while the personality politics of last year’s sweary WhatsApps may make good newspaper copy, the public are more focused on the here and now of why the Indian variant has been allowed to let rip.Raising again the issue of proper payments for self-isolation (on the day it seems the Cabinet Office has its own internal document urging just that), plus the ending of business rate relief and full furlough, showed he was talking to immediate concerns not historic ones. Hospitality and small businesses groups contacted Starmer after PMQs thanking him for raising their lack of support and clarity, I’m told.And Starmer’s strategic target is of course the PM himself. That’s why Labour talks about ‘the Johnson variant’ of the virus and it’s why it will keep hammering its message that lax border controls may have undermined all the hard work of both the public and the NHS’s vaccine programme.Yet there was material in the Cummings blog that will come in useful in attacking Johnson. We learned for the first time that the PM had texted to his advisers “how do we win the herd immunity argument?” The full text of that was frustratingly not reproduced (and Johnson is bound to argue he didn’t go ahead with that argument anyway).The account of how Johnson runs meetings, avoiding conflict, failing to ask proper questions to officials, “doing a thumbs-up and pegging it out of the room before anybody can disagree”, sounded all too realistic. This at least proved the PM is as blithe in private as he is in public, but it’s a worrying lack of leadership nevertheless. Starmer, in the G7 statement later, had a wounding line that Johnson was a “host, not a leader, a tour guide, not a statesman”.For his part, Johnson in PMQs showed again why he’s a formidably cynical politician. Every question was batted away with “Brexit, vaccines, flip-flop Starmer, Brexit, vaccines, flip-flop Starmer”. His jibe that “Captain Hindsight needs to adjust his retrospectoscope” was actually pretty funny.Faced with such spin and sleight of hand, Starmer can only hope that the public will one day tire of the jokes and the failures of governance. He needs to combine the air of being a grown-up in the room with his own message of optimism, just as Joe Biden persuaded Americans that the crazy years had to be followed by calm good government.If Labour can at the next election persuade the voters that it is Boris Johnson who was “fucking hopeless” in keeping Covid under control, that’s a much bigger prize than giving Dominic Cummings the scalp of the health secretary. The party needs big answers on big issues like childcare, social care and life chances too. But Starmer at least has his eyes on the real target.Related...Hancock Confirms Plan To Make Covid Vaccines Compulsory For All NHS And Care WorkersBoris Johnson Plans To Quit As PM To ‘Make Money And Have Fun’ By 2026, Cummings ClaimsBoris Johnson Called Matt Hancock ‘Totally F**king Hopeless’ In WhatsApp Message
Buckeye State legislature looks on as key, hairpin fall off of entirely unmagnetic nurse A registered nurse helped the US on its seemingly inevitable descent into terminal conspiracy-induced intellectual collapse last week when she stood in front of the Ohio state legislature and attempted to convince lawmakers that COVID-19 vaccinations "magnetise" their recipients.…
Matt Hancock has confirmed that Covid vaccination is to be a condition of employment for care home staff and that the government will consult on a similar rule for NHS staff.The health secretary told MPs of the move, despite opposition from Labour, trade unions and others who fear it could prove counter-productive.Speaking in the Commons, Hancock said: “The vast majority of staff in care homes are already vaccinated but not all, and we know that the vaccine not only protects you but protects those around you.“Therefore we will be taking forward the measures to ensure the mandation as a condition of deployment for staff in care homes and we will consult on the same approach in the NHS in order to save lives and protect patients from disease.”He added that he would now consult on whether all healthcare staff, including those in the NHS and domiciliary care, should face similar rules.“The principle of vaccination for those in a caring responsibility is already embedded and indeed there is a history going back more than a century of vaccination being required in certain circumstances, and I think these are reasonable circumstances.“So, we will go ahead for those who work in care homes and we will consult for those in domiciliary care and on the NHS.”He added that he had no wider proposals to make the vaccinations compulsory for the public, but did say that the state had a lesser “duty” toward those who had refused to be jabbed.Former minister Steve Baker suggested carers should have a right to choose between the vaccine or daily lateral flow tests, but Hancock replied: “It is a matter of risk and we know the vaccine reduces that risk very significantly.”The prime minister’s official spokesperson said that no vote by MPs would be required to enact the change. “I don’t believe this is something that would be voted on in parliament,” he said.England’s chief medical officer, Professor Chris Whitty, has said doctors and care workers have a “professional responsibility” to protect their patients, just as they already have a “duty” to get jabbed for hepatitis B.But the backlash against making Covid vaccinations effectively compulsory for care home staff began in earnest, with some in the sector warning it would make it harder to attract badly-needed employees and could lead to some quitting.The GMB union claimed more than a third of carers would consider leaving their jobs if vaccinations become compulsory.NHS figures to June 6 show overall that 84% of staff in older adult care homes in England have had one dose of vaccine, and almost 69% have had both jabs.But the data shows that in Hackney, east London, for example, just 66.7% of staff in older adult care homes have had their first dose, with only 58.6% of staff in the borough having both doses.Dr Susan Hopkins, strategic response director for Covid-19 at Public Health England, told MPs “people may vote with their feet, and not want to have the vaccine, and therefore not work in a care home, and that could lead to staff supply issues in care homes”.She told the Science and Technology Committee: “I will remain a little bit concerned that we will have shortages of care staff once the mandate has come in, but I’m sure that the vast majority of care workers do want to do the right thing and get vaccinated to protect the elderly under their care.”Research published last month by the London School of Hygiene & Tropical Medicine (LSHTM) found Black African and mixed Black African staff are almost twice as likely to decline a vaccination as white British and white Irish participants.Reasons included concerns about a lack of research and distrust in the vaccines, healthcare providers, and policymakers.Unison general secretary Christina McAnea said: “The only way out of the pandemic is for everyone that can to have their jabs. Encouragement has the best results and research shows coercion makes the nervous less likely to be vaccinated.“The government’s sledgehammer approach now runs the risk that some care staff may simply walk away from an already understaffed, undervalued and underpaid sector.”GMB national officer Rachel Harrison said: “The government could do a lot to help care workers: address their pay, terms and conditions, increasing the rate of and access to contractual sick pay, banning zero hours, and ensuring more mobile NHS vaccination teams so those working night shifts can get the jab.“Instead, ministers are ploughing ahead with plans to strong-arm care workers into taking the vaccine without taking seriously the massive blocks these workers still face in getting jabbed.”Mike Padgham, chairman of the Independent Care Group (ICG) which represents care homes in Yorkshire, said “it will put people off coming into the service”.“The second problem is people who are already working in the service who might not want the vaccine. We are so stretched for frontline staff. It sounds easy to redeploy them but it isn’t easy to replace them when you redeploy them. And I think people will be put off.”Director of public health for Gateshead, Alice Wiseman, told Times Radio she backed the move, saying: “This is a really difficult decision because nobody ever wants to take away an individual’s right to have that choice.“But we do make some vaccines mandatory in other aspects of healthcare. So, for example, we ensure all surgeons have their hep B vaccination, and it’s really important that we do this where we’re protecting those people who we are caring for.”Related...Boris Johnson Called Matt Hancock ‘Totally F**king Hopeless’ In WhatsApp MessageMatt Hancock Denies Lying To Boris Johnson About Covid PandemicTwo Covid Vaccine Doses 'Highly Effective' Against Delta Variant Hospitalisation